Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB/II Study of Second Line Therapy With Panitumumab, Irinotecan and Everolimus (PIE) in Metastatic Colorectal Cancer With KRAS WT

NCT01139138 is registered in ClinicalTrials.gov with The Queen Elizabeth Hospital as lead sponsor.

NCT NCT01139138
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01139138 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB/II Study of Second Line Therapy With Panitumumab, Irinotecan and Everolimus (PIE) in Metastatic Colorectal Cancer With KRAS WT
Lead sponsor
The Queen Elizabeth Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2010
Completion date
June 30, 2017
Enrollment
49 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, colorectal carcinoma, colorectal tumors, neoplasms, colorectal